Yang, Riyao
Huang, Su
Huang, Cai
Fay, Nathan S.
Wang, Yanan
Putrevu, Saroja
Wright, Kimberly
Zaman, Mohd Saif
Cai, Wenyan
Huang, Betty
Wang, Bo
Wright, Meredith
Hoag, Matthew R.
Titong, Allison
Liu, Yue
Article History
Received: 20 January 2023
Accepted: 13 June 2023
First Online: 18 June 2023
Competing interests
: All authors of this study are current or former employees at Ab Therapeutics Inc. or Ab Studio Inc. that develop commercial therapeutic antibodies. Yue Liu serves as the Chief Executive Officer for both Ab Therapeutics inc. and Ab Studio Inc. that commercially develop therapeutic antibodies.